1. Cancer

Cancer

Cancer is a neoplastic disease caused by uncontrolled division of abnormal cells in a part of the body and their subsequent local invasion and systematic metastasis to other parts of the body. Oncogenic mutations, genome instability and inflammation initiate and expedite the acquisition of several hallmarks by cancer cells such as sustaining unlimited growth, resisting cell death, inducing angiogenesis, activating invasion and metastasis, reprogramming cellular metabolism, and evading immune checkpoints. Our large repertoire of cancer related small molecules are designed to facilitate both basic research on cancer biology and developing new strategies to treat cancer.

Cancer Related Products (3578):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-10219
    Rapamycin 53123-88-9 99.93%
    Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator.
    Rapamycin
  • HY-13259
    MG-132 133407-82-6 >98.0%
    MG-132 is a potent, reversible, and cell-permeable 20S proteasome inhibitor which inhibits proteasomal chymotrypsin-like peptidase activity with an IC50 of 24.2 nM.
    MG-132
  • HY-19312
    3-Methyladenine 5142-23-4 99.84%
    3-Methyladenine is a PI3K inhibitor. 3-Methyladenine is a widely used inhibitor of autophagy via its inhibitory effect on class III PI3K.
    3-Methyladenine
  • HY-10108
    LY294002 154447-36-6 99.95%
    LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively. It also inhibits CK2 with an IC50 of 98 nM.
    LY294002
  • HY-16658
    Z-VAD(OMe)-FMK 187389-52-2 >98.0%
    Z-VAD(OMe)-FMK is a cell-permeable and irreversible pan-caspase inhibitor.
    Z-VAD(OMe)-FMK
  • HY-10162
    Olaparib 763113-22-0 99.71%
    Olaparib (AZD2281;KU0059436) is a potent and oral PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively.
    Olaparib
  • HY-17394
    Cisplatin 15663-27-1 >99.0%
    Cisplatin is a antineoplastic chemotherapy drug which works by cross-linking with DNA and causing DNA damage in cancer cells.
    Cisplatin
  • HY-13030
    (+)-JQ-1 1268524-70-4 99.90%
    (+)-JQ-1 is a BET bromodomain inhibitor, with IC50s of 77 and 33 nM for the first and second bromodomain (BRD4(1/2)).
    (+)-JQ-1
  • HY-15142
    Doxorubicin hydrochloride 25316-40-9 99.47%
    Doxorubicin hydrochloride is a cytotoxic anthracycline antibiotic for the treatment of multiple cancers. The possible mechanisms by which doxorubicin acts in the cancer cell are intercalation into DNA and disruption of topoisomerase-II-mediated DNA repair.
    Doxorubicin hydrochloride
  • HY-12041
    SP600125 129-56-6 98.82%
    SP600125 is a reversible and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively.
    SP600125
  • HY-17559
    Actinomycin D 50-76-0 99.89%
    Actinomycin D inhibits DNA repair with an IC50 of 0.42 μM.
    Actinomycin D
  • HY-13316
    Mitomycin C 50-07-7 98.89%
    Mitomycin C is an antitumor drug and antibiotic that shows extraordinary ability to inhibit DNA synthesis.
    Mitomycin C
  • HY-12031
    U0126 1173097-76-1 98.06%
    U0126 is a potent and non-ATP competitive MEK1 and MEK2 inhibitor, with IC50s of 70 nM and 60 nM, respectively.
    U0126
  • HY-B0015
    Paclitaxel 33069-62-4 99.97%
    Paclitaxel (Taxol) is a potent anticancer medication which can promote microtubule (MT) assembly, inhibit MT depolymerization, and change MT dynamics required for mitosis and cell proliferation.
    Paclitaxel
  • HY-10583
    Y-27632 dihydrochloride 129830-38-2 99.83%
    Y-27632 dihydrochloride is a cell-permeable, ATP-competitive inhibitor of ROCK-I and ROCK-II, with Kis of 220 and 300 nM, respectively.
    Y-27632 dihydrochloride
  • HY-10182
    CHIR-99021 252917-06-9 99.76%
    CHIR-99021 is a GSK-3α/β inhibitor with an IC50 of 10 and 6.7 nM,showing 500-fold selectivity over its closest homologs CDC2 and ERK2, as well as other protein kinases.
    CHIR-99021
  • HY-15531
    Venetoclax 1257044-40-8 99.95%
    Venetoclax (GDC-0199; ABT-199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM.
    Venetoclax
  • HY-70002
    Enzalutamide 915087-33-1 99.71%
    Enzalutamide (MDV3100) is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells.
    Enzalutamide
  • HY-17471A
    Metformin hydrochloride 1115-70-4 99.98%
    Metformin (hydrochloride) is an FDA approved first-line drug for the treatment of type 2 diabetes. Metformin decreases hepatic glucose production, mostly through a mild and transient inhibition of the mitochondrial respiratory-chain complex 1.
    Metformin hydrochloride
  • HY-10201
    Sorafenib 284461-73-0 99.92%
    Sorafenib (Bay 43-9006) is a potent multikinase inhibitor with IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.
    Sorafenib